NEW YORK | Sun Oct 17, 2010 8:07am EDT
NEW YORK (Reuters) - The Food and Drug Administration on Friday approved Allergan Inc's anti-wrinkle injection Botox to treat chronic migraines.
Botox injections would be given to adult sufferers of chronic migraines around the head and neck every 12 weeks in an attempt to dull future headaches, said the FDA in a statement.
Chronic migraine sufferers have a headache on most days of the month. Botox has not been shown to work for people who suffer headaches 14 days or less per month, the FDA said.
The United Kingdom was the first country to approve the use of Botox for migraine treatment in July.
The approval comes just over a month after Allergan agreed to pay $600 million to settle a federal probe into its marketing practices for Botox.
Allergan Inc's shares rose 7 percent in after-hours trading to $73.90.
(Reporting by Helen Kearney; Editing by Gary Hill)
A variety of drugs have been specifically designed to treat migraines. In addition, some drugs commonly used to treat other conditions also may help relieve or prevent migraines. Medications used to combat migraines fall into two broad categories: